Magnetic Ventures

Project Eaden is a developer of a food technology platform focused on creating sustainable food products that serve as alternatives to meat. By leveraging innovative technology, the company aims to address consumer cravings for beef and beef products while promoting environmentally friendly options. Through its offerings, Project Eaden seeks to combine a passion for life and food with a commitment to sustainability, providing consumers with viable alternatives that align with modern dietary preferences and concerns.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Transition Bio, Inc. is a biotechnology company that specializes in the discovery, analysis, and modulation of biological condensates. Established in 2020 and headquartered in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom, the company has developed a unique platform known as Condensomics. This hypothesis-free drug discovery and diagnostics technology allows for expansive opportunities in drug development by leveraging the intricate properties of biological condensates. Transition Bio's innovative approach aims to advance the understanding and application of these biological structures in the field of medicine.

Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body. The company's therapeutics are used to create next-generation programmable nucleases that can selectively target and edit cells, enabling physicians to treat their patient in an enhanced way.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.

AppliedVR, Inc. specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, specifically for managing pain and anxiety in various settings such as hospitals and surgery centers across the United States. Founded in 2013 and based in Los Angeles, the company has established partnerships with leading healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles. Its therapeutic virtual reality platform has been utilized by over 20,000 patients in more than 250 hospitals and in eight countries. The technology is designed to address both acute and chronic pain, as well as anxiety related to medical procedures, offering clinically validated, on-demand solutions. Inspired by extensive academic research, AppliedVR seeks to redefine pain management practices in clinical environments and at home, aiming to establish itself as a leading digital health solution provider in this field.

ConsejoSano offers multicultural engagement and navigation solutions for health plans, providers, states to help guide culturally diverse populations through the complexities of the health care system and drive improved performance, outcomes and satisfaction.

Resilience is a biopharmaceutical manufacturing and technology company based in La Jolla, California, established in 2020. It aims to enhance access to complex medicines and safeguard biopharmaceutical supply chains. The company specializes in end-to-end manufacturing and development solutions across various therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. Resilience provides customized manufacturing capabilities that cater to the diverse needs of biopharmaceuticals at all stages of the drug development process, from pre-clinical development to commercial supply. With a focus on developing new manufacturing technologies, Resilience ensures high-quality and regulatory-compliant processes for complex and novel medicines.

Emme, Inc. is a healthcare technology company based in San Francisco, California, focused on improving women's reproductive health through innovative solutions. The company designs and develops an integrated smart case device and mobile application aimed at helping women adhere to their birth control regimens by reducing the incidence of missed pills. The Emme Smart Case employs multi-sensor technology to track pill intake and provides notifications when back-up contraception is needed. Additionally, the accompanying app offers users a comprehensive platform to monitor various aspects of their health, including menstrual cycles, mood, and side effects. By combining these technologies, Emme aims to empower women to take control of their reproductive health in a modern and user-friendly manner.

Amagma Therapeutics is a biotechnology company that specializes in the discovery and development of antibody therapeutics against inflammatory diseases. Its technology overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses. The company was founded in 2019 and headquartered in Waltham, Massachusetts.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.